drugset / Trial / NCT05744063
A Post-authorization Study to Describe the Safety and Efficacy of Emapalumab for the Treatment of pHLH in Treatment Experienced Chinese Patients
NaSingle-groupOpen-labelTreatment
Summary
The goal of this post-authorization study is to describe safety and efficacy of emapalumab in treatment experienced Chinese patients with pHLH.
Timeline
- Start
- 2023-02-03
- Primary completion
- 2025-02-21
- Completion
- 2025-08-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Emapalumab | Monoclonal antibody | 1 mg/kg | — |